The European Commission (EC) has granted marketing authorisation for Aucatzyl (obecabtagene autoleucel or ‘obe-cel’) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL). The EC approval was based on the results of the FELIX study, an open-label, multi… Read More
A new chimeric antigen receptor T cell (CAR-T) therapy has delivered highly promising results in treating patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL). The FELIX clinical trial was led by researchers at University College London (UCL) and UCLH and sponsored by UCL spin-out Autolus Therapeutics. Read More
The US Food and Drug Administration (FDA) has approved Autolus’ obecabtagene autoleucel (Aucatzyl), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). The efficacy of obecabtagene autoleucel was evaluated in FELIX, an open-label, multicentre, single-arm… Read More
